A Clinical Trial of a 3-dose, 28-Day Regimen of PfSPZ Vaccine in Healthy, Malaria-Naïve, Adult Subjects to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI Conducted 14, 42 or 70 Days After Immunization
Latest Information Update: 19 Jul 2022
At a glance
- Drugs Malaria vaccine live attenuated-Sanaria (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanaria
- 15 Jul 2022 Status changed from recruiting to completed.
- 04 Apr 2022 Planned primary completion date changed from 1 Mar 2022 to 1 May 2022.
- 01 Oct 2021 Planned End Date changed from 1 Jan 2022 to 1 May 2022.